Access to Information Requests Completed - March 2013

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the month of March 2013

Request #	Summary of Requests	Status of Completed Request	Number of Pages Disclosed
A-2010-00583	All documents related to the interdepartmental Working Group on Animal Biotechnology. (Jun 1, 2009 to Aug 1, 2010).	Disclosed in part	77
A-2010-00899	All documents regarding childhood obesity and high-calorie foods, including sugar-sweetened drinks or similarly-described beverages. (Nov 26, 2009 to Nov 25, 2010).	Disclosed in part	2,045
A-2010-01166	All correspondence between Health Canada and The Canadian Cancer Society. (Oct 15, 2008 to Jan 20, 2011).	Disclosed in part	3,333
A-2010-01534	Documents regarding the First Nations & Inuit Health (FNIH) - Pacific Regions Regional Review Committee's comments and recommendations in regard to the 2009 British Columbia Aboriginal Network on Disability Society submitted Business.	Disclosed in part	73
A-2010-01536	Correspondence between the First Nations & Inuit Health (FNIH) - Pacific Regions Regional Review Committee and the British Columbia Aboriginal Network on Disability Society (BCANDS). (Apr 1, 2007 to Dec 20, 2010).	Disclosed in part	1,281
A-2011-00151	All adverse reaction and final risk to health and safety assessments reports for the following producst: Artecoll, Arteplast, Artefill/Artefil, and Artesense. (Mar 24, 2000 to May 2, 2011).	Disclosed in part	167
A-2011-00250	All documents produced in 2011 with regard to outcome indicators specified in the funding agreement with Canada Health Infoway Inc.	Disclosed in part	30
A-2011-00251	All documents produced in 2010 with regard to outcome indicators specified in the funding agreement with Canada Health Infoway Inc.	Disclosed in part	153
A-2011-00387	All documents that was reviewed by the ad hoc scientific/expert advisory panel convened by Health Canada on or about October 26, 2010 regarding caffeinated energy dinks.	Disclosed in part	480
A-2011-00511	Information reported by every tobacco manufacturer and importer under clauses 9(1)(a), 9(1)(b) and 9(1)(c) of the Tobacco Reporting Regulations.	Disclosed in part	259
A-2011-00543	2010, 2011 briefing notes, reports, medical device incident/investigative reviews on reprocessing medical devices previously used being reused by unauthorized third parties who are selling these reprocessed products to Canadian hospitals.	Disclosed in part	56
A-2011-00644	All adverse reaction and final risk to health and safety assessments reports for the following producst: Artecoll, Arteplast, Artefill/Artefil, and Artesense. (May 3, 2011 to Aug 31, 2011).	Disclosed in part	9
A-2011-01059	Documents relating to Health Canada's 2011 input and review of drug price cost impact analyses studies/projections/estimates or briefing notes and exchanges on possible domestic drug price costs given proposed European Union pharmaceutical intellectual property changes in the negotiations for a comprehensive economic and trade agreement (CETA).	Disclosed in part	296
A-2011-01434	Information regarding the product Florabile, NPN 02061619 by Les Laboratoires Suisse Inc.	All disclosed	28
A-2011-01435	Information regarding the product Trophic Digest-Aid, NPN 00141291 by Trophic Canada.	Disclosed in part	27
A-2011-01444	Information regarding the product Silica, NPN 02237471 by General Nutrition Centres Company.	Disclosed in part	56
A-2011-01539	Information regarding the product PMS-Testosterone, DIN 02322498 by Pharmascience Inc.	Disclosed in part	334
A-2011-01675	Information regarding the product CLARITIN ALLERGY DECONGESTANT, DIN 02243690.	Disclosed in part	17
A-2012-00001	Correspondence between Health Canada and the manufacturers and markets of Cold FX (including unpublished reports about the truth, efficacy and claims). (Jan 1 2010 to Apr 2, 2012).	Disclosed in part	920
A-2012-00084	AERs for the product PRADAX. Report numbers: 000370589, 000372959 and 000356740.	Disclosed in part	6
A-2012-00096	Copies of every inquiry made to status@hc-sc.gc.ca and the response, if any, from Health Canada. (Jan 1, 2011 to Apr 19, 2012).	Disclosed in part	3,156
A-2012-00100	Documents related to any initiative to improve processing time and efficiency of handling access to information requests. (Apr 20, 2011 to Apr 19, 2012).	All disclosed	30
A-2012-00130	All correspondence with representatives of the Canadian Council for Tobacco Control. (Jan 1, 2011 to May 1, 2012).	Disclosed in part	98
A-2012-00159	AER. Report number: 000371648.	Disclosed in part	16
A-2012-00187	All documents regarding the government's decision to close Assisted Human Reproduction Canada effective March 1 2013. (Sep 1, 2011 to Oct 7, 2011).	All excluded	0
A-2012-00188	All documents regarding the government's decision to close Assisted Human Reproduction Canada effective March 1 2013. (Oct 1, 2011 to Nov 1, 2011).	All excluded	0
A-2012-00190	All documents regarding the government's decision to close Assisted Human Reproduction Canada effective March 1 2013. (Dec 1, 2011 to Jan 1, 2012).	All excluded	0
A-2012-00192	All documents regarding the government's decision to close Assisted Human Reproduction Canada effective March 1 2013. (Feb 1, 2012 to Mar 1, 2012).	Disclosed in part	12
A-2012-00200	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for the product Perigee System with Intepro. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	82
A-2012-00261	All documents related to approval of American Health Systems Transvaginal Mesh / Pelvic Support Mesh / Sling, for the product GYNECARE PROLIFT +M Pelvic Floor Repair System. (Jan 1, 1996 to May 7, 2012).	Disclosed in part	19
A-2012-00323	All documents sent to the Minister showing on what date the Minister of Health Canada was made aware of the report stating that radon levels were too high in 10% of federal buildings. (Jun 1, 2011 to May 31, 2012).	All disclosed	4
A-2012-00420	All communications between Health Canada and the following organizations: Canadian Wind Energy Association, Acciona Wind Energy Canada Inc., AIM PowerGen Corporation, Aercoustics Engineering Corp., Canadian Hydro Developers Inc., Enbridge Inc., Garrad Hassan Canada Inc., Jacques Whitford Limited, Kruger Energy Inc., Suncor Energy Products Inc., TransAlta Wind, TransCanada Energy Ltd. (Jan 1, 2009 to Jun 15, 2012)	Disclosed in part	178
A-2012-00465	All documents relating to application for a Temporary Marketing Authorization Letter to permit the marketing in Canada of Silk True Coconut Beverage, a fortified coconut milk beverage.	Disclosed in part	193
A-2012-00518	All documents about so-called pink slime in ground beef (burgers). (Jan 1, 2011 to Jun 30, 2011).	Disclosed in part	110
A-2012-00566	Information regarding the product Mylan-bosentan by Mylan Pharmaceuticals ULC.	Disclosed in part	532
A-2012-00607	Documents concerning the decision to conduct a study on the health impact of living near wind power turbines.	Disclosed in part	256
A-2012-00633	Information regarding the approval of the Product Monograph (dated October 2006) for Tysabri (natalizumab).	Disclosed in part	764
A-2012-00686	All documents regarding the meeting with the joint Canadian Tanning Association held on February 28, 2012.	Disclosed in part	471
A-2012-00838	All documents mentioning the Heart & Stroke Foundation regarding the following: 1) Chronic disease, including healthy eating or active living; 2) Strategies to address heart and stroke conditions and/or diabetes; 3) Sodium reduction; 4) Medications, pricing, patient access or approval;  and 5) any contact between the organisations and Health Canada staff in the Minister's office. (Sep 1, 2011 to Aug 22, 2012).	Disclosed in part	199
A-2012-00840	All documents mentioning the Canadian Diabetes Association regarding the following: 1) Chronic disease, including healthy eating or active living; 2) Strategies to address heart and stroke conditions and/or diabetes; 3) Sodium reduction; 4) Medications, pricing, patient access or approval;  and 5) any contact between the organisations and Health Canada staff in the Minister's office. (Sep 1, 2011 to Aug 22, 2012).	Disclosed in part	121
A-2012-00925	AERs for the product Mirena. Report numbers: 000425532, 000429935, 000430968, 000431342, 000431598 and 000431600.	Disclosed in part	24
A-2012-00933	Documents relating to Health Canada's business with Aboriginal Affairs and Northern Development Canada (AANDC), its case management system called Single Access to Dispute Resolution Enterprise (SADRE), and related support systems: Electronic Data Interchange (EDI), Integrated File Management System (IFMS), and SharePoint information sharing. (Jan 1, 2006 to Sep 19, 2012).	Disclosed in part	1,286
A-2012-00958	Medical Marihuana Access Program. Information regarding stakeholders 7 committees working to commercial growers of marihuana, proposals regarding: Opportunity for those interested in becoming a licensed commercial producer.	Disclosed in part	161
A-2012-00960	Information regarding the product Helixia Sinus, NPN 80030626 by Cassella-med GmbH & Co. KG.	Disclosed in part	195
A-2012-00987	AERs for the product Nexavar. Report numbers: 000436650, 000438292, 000438748, 000438749, 000438752, 000439563, 000439564, 000439565, 000439566, 000439583,000440112, 000440113, 000440114, 000440115 and 000440116.	Disclosed in part	18
A-2012-01041	Information regarding the product Nasonex (Mometasone Furoate) by Merck Canada Inc.	Disclosed in part	238
A-2012-01047	Information regarding the product Marzine, DIN 00004448 by Glaxo Wellcome Inc.	Disclosed in part	7
A-2012-01052	AERs for the product Celexa. Report numbers: 000443492, 000430918 and 000425171.	Disclosed in part	14
A-2012-01090	Information regarding the product DERMAFLEX HC 1% LOTION, DIN 00681997 by Triton Pharma Inc.	Disclosed in part	54
A-2012-01162	All reviews, studies, reports, audits, and assessments, on Employee Assistance Services and/or Employee Assistance Program provided by Health Canada and on the group that offers employee assistance services and/or programs. (Jan 1, 2009 to Nov 21, 2012).	Disclosed in part	801
A-2012-01165	Information regarding the product Eltroxin Tablets (Levothyroxine sodium).	Disclosed in part	271
A-2012-01202	The health risk assessment of energy drinks, which was referenced in Health Canada's Proposed Management Approach in Response to the Expert Panel on Caffeinated Energy Drinks in October 2011.	All exempted	0
A-2012-01224	Information regarding the products Whey Iso Burst (Banana Berry Burst; Double Chocolate Royale; French Vanilla Cream; Creamy Raspberry Swirl; Outrageous Orange Cream; Natural), NPN 80035652 by General Nutrition Centres Company.	Disclosed in part	5
A-2012-01230	All documents concerning the Canadian Guidelines for Wind Turbine Noise Working Group of the Federal/Provincial/Territorial Committee on Health and the Environment. (Oct 1, 2011 to Nov 26, 2012).	Disclosed in part	399
A-2012-01241	All documents regarding the amounts allocated to Quebec for integrating physicians who studied outside Canada and the United Sates. (Apr 1, 2011 to Nov 28, 2012).	All disclosed	55
A-2012-01257	Information regarding the product ARIMIDEX, DIN 02224135 by AstraZeneca Canada Inc.	Disclosed in part	49
A-2012-01270	Information regarding the products Quiex-Forte, DIN 02011654 and Quiex-Pred, DIN 02011662.	Disclosed in part	10
A-2012-01284	All documents related to meetings between officials from Health Canada and Sandoz Canada Inc. held on the following dates: August 18, 2011, November 24, 2011, March 14, 2012, April 3, 2012 and May 1, 2012 regarding Oxycontin.	No records exist	0
A-2012-01294	AERs for the medical device Waverly Glen p440 Ceiling Track Life System. (Jan 1, 2009 to Dec 3, 2012).	Disclosed in part	314
A-2012-01296	All documents outlining the total cost of cellphone/smartphone bills paid by the department for fiscal years 2010, 2011 and 2012.	All disclosed	1
A-2012-01330	AERs for the product BIAXIN. Report numbers: 000398216, 000380550, 000382510, 000384973 and 000390455.	Disclosed in part	12
A-2012-01349	Information regarding the product MONICURE COMBO, DIN 02382628 by Insight Pharmaceuticals LLC.	Disclosed in part	102
A-2012-01378	All documents regarding the Adverse Reaction Reports for Morphine. (Jan 1, 2009 to Jan 21, 2013).	All disclosed	75
A-2012-01380	All documents regarding the Adverse Reactions Reports for Acetaminophen. (Jan 1, 2009 to Jan 21, 2013).	All disclosed	155
A-2012-01384	AER. Report number: 000436065.	Disclosed in part	6
A-2012-01389	Information regarding the product Tridural by Labopharm Inc.	All disclosed	2
A-2012-01393	Information regarding the product Feramax Powder Water Soluble Polysaccharide-Iron Complex, NPN 80033717 by Bio Syent Pharma Inc.	Disclosed in part	43
A-2012-01406	Information regarding the product Sh-206 Shampoo, NPN 01992902 by Pharmascience Inc.	Disclosed in part	24
A-2012-01410	AERs for the product Biaxin. Report numbers: 000398725, 000412815, 000416055, 000417418, 000418432, 000418744 and 000422267.	Disclosed in part	9
A-2012-01435	All documents related to the applicant, who is authorized to provide dental services under Health Canada's Non-Insured Health Benefits Program, identified in the following legal matter: http://www.canlii.org/en/on/onhparb/doc/2012 /2012 canlii69046/2012canlii69046.html.	Disclosed in part	157
A-2012-01438	All documents related to the development of new cigarette warning labels. (Jan 1, 2005 to Jul 1, 2005).	Disclosed in part	173
A-2012-01445	All documents related to the regulation of pet foods in Canada.	All disclosed	9
A-2012-01447	Any reports or summaries produced of water quality testing on First Nations reserves in British Columbia. (Jan 1, 2012 to Jan 15, 2013).	Disclosed in part	98
A-2012-01460	AER for the product Epival. Report number: 000414734.	Disclosed in part	2
A-2012-01468	All reports, briefing materials and memos produced for the Minister pertaining to caffeinated energy drinks and/or energy shots. (Sep 1, 2012 to Jan 18, 2012).	All disclosed	11
A-2012-01476	Comments received in response to the October 25, 2012 information and notification document on Health Canada's proposal to enable the use of Dimethyl dicarbonate as a preservative in wine and in unstandardized water based non-alcoholic beverages.	No records exist	0
A-2012-01477	All correspondence between Robert Friesen lobbyist registration number 733754-245322-3, including correspondence on behalf of any of his clients, and the Minister of Health and/or her exempt staff.	No records exist	0
A-2012-01495	All documents regarding total annual monetary expenditures and cash costs for moves to Canada and abroad by civil servants in your department or organization. (Jan 1, 2005 to Jan 29, 2013).	All disclosed	14
A-2012-01503	Any information concerning the volume of sales of ACTOS in Canada.	No records exist	0
A-2012-01508	A listing of the Access to Information requests submitted to Health Canada. (Sep 1, 2012 to Sep 30, 2012).	Disclosed in part	5
A-2012-01509	A listing of the Access to Information requests submitted to Health Canada. (Oct 1, 2012 to Oct 31, 2012).	Disclosed in part	9
A-2012-01510	A listing of the Access to Information requests submitted to Health Canada. (Nov 1, 2012 to Nov 30, 2012).	Disclosed in part	11
A-2012-01520	All call-ups/Contracts processed by this institution in the National Capital Region under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services during the period of January 2013.	Disclosed in part	83
A-2012-01522	All correspondence to and from Marcy Richard, Program Manager - National Native Alcohol and Drug Abuse Program, First Nations an Inuit Health, Manitoba Region with respect to or making mention of the RedPath Mobile Addiction Treatment Program, Mobile Addiction Treatment, the RedPath Program(s) and training and/or Whitepath Consulting Inc. (Jan 1, 2012 to Jan 31, 2013).	Disclosed in part	11
A-2012-01526	All correspondence to and/or from Noelle Greene, Regional Director, Human Resources, Health Canada, mentioning the Ancien Group. (Jan 1, 2009 to Jan 17, 2013).	No records exist	0
A-2012-01527	Briefing notes, reports, studies and memos regarding Benzodiazepine addiction. (Jan 1, 2011 to Feb 6, 2013).	All disclosed	25
A-2012-01528	All correspondence to and/or from Noelle Greene, Regional Director, Human Resources, Health Canada, mentioning Joelle Fougere. (Jan 1, 2009 to Jan 17, 2013).	No records exist	0
A-2012-01531	All correspondence to and/or from the Director General, Human Resources at Health Canada, mentioning the Ancien Group. (Jan 1, 2009 to Jan 17, 2013).	No records exist	0
A-2012-01533	All correspondence to and/or from the Director General, Human Resources at Health Canada, mentioning Joelle Fougere. (Jan 1, 2009 to Jan 17, 2013).	No records exist	0
A-2012-01535	AER. Report number: 000417497.	Disclosed in part	3
A-2012-01559	AERs for the product Alprazolam. Report numbers: 000078433, 000078436, 000085818, 000088782, 000117469, 000137952, 000173856, 000179863, 000181846, 000305194, 000347060, 000356065 and 000462096.	Disclosed in part	46
A-2012-01561	All documents regarding the number of complaints for various types of physical, sexual or verbal harassment involving one or more civil servants in your department or organization. (Jan 1, 2005 to Feb 9, 2013).	All disclosed	1
A-2012-01568	Documents regarding the Non-Insured Health Benefits for approved/rejection sales for procedures requiring pre-approval/pre-determination and statistics or appeals for services including first second and third level appeals for orthodontics in Nunavut.	All disclosed	12
A-2012-01574	Information regarding the product Multihance, DIN 02248302 by Bracco Imaging Canada.	Disclosed in part	796
A-2012-01575	AER for the product Biaxin. Report number: 000435848.	Disclosed in part	1
A-2012-01581	All inspections and investigations done by the Canadian Food Inspection Agency pertaining to Archers Poultry located in Brighton, Ontario. (Jan 1, 2007 to Feb 18, 2013).	No records exist	0
A-2012-01586	All documents relating to media requests about Health Canada's decision (announced October 18, 2012) to create a web-based listing of clinical trials information in Canada.	All disclosed	11
A-2012-01589	A list of the products and ingredients that were listed as being tested by Chemi-Pharmaceutical Inc., of Mississauga,Ontario.  It was removed from the Health Canada web site on January 7, 2013.	All disclosed	18
A-2012-01597	AER for the product Avelox. Report number: 000460050.	Disclosed in part	1
A-2012-01598	AER for the product Betaseron. Report number: 000455930#.	Disclosed in part	2
A-2012-01599	AERs for the product Cipro. Report numbers: 000454425, 000456651 and 000457662.	Disclosed in part	4
A-2012-01600	AER for the product Gadovist. Report number: 000459130.	Disclosed in part	1
A-2012-01601	AERs for the product Mirena. Report numbers: 000454922, 000454946 and 000455264.	Disclosed in part	4
A-2012-01602	AER for the product Nexavar. Report number: 000454824.	Disclosed in part	2
A-2012-01603	AER for the product Visanne. Report number: 000458573.	Disclosed in part	2
A-2012-01605	A copy of all questions submitted to the Employee Corner, BC Tripartite Question and Answers. (http://app40/cmcd/bcintranet.nsf/content- contenu/2011- 00416?OpenDocument&id==FromSearch &lang=E&)	Disclosed in part	141
A-2012-01613	The aggregate average processing time taken to complete applications for an Authorization to Possess Dried Marihuana during 2012.	All disclosed	1
A-2012-01615	AER for the product Evista. Report number: 000379363.	Disclosed in part	1
A-2012-01617	AERs for the product Cymbalta. Report numbers: 000380546, 000381430, 000381433, 000381613, 000381872, 000384893, 000387309, 000389748, 000395056 and 000395286.	Disclosed in part	14
A-2012-01621	AERs for the product Adcirca. Report numbers: 000420248 and 000421341.	Disclosed in part	4
A-2012-01622	AERs for the product Alimta. Report numbers: 000418749 and 000426057.	Disclosed in part	2
A-2012-01625	AERs for the product Cymbalta. Report numbers: 000426059, 000426686, 000429980, 000429987, 000436692, 000437377, 000439018, 000439025, 000440909 and 000442406.	Disclosed in part	14
A-2012-01627	AER for the product Effient. Report number: 000416037.	Disclosed in part	1
A-2012-01628	AER for the product Forteo. Report number: 000444857.	Disclosed in part	2
A-2012-01634	AERs for the product Cymbalta. Report numbers: 000415268, 000458324, 000459276, 000460042, 000460255, 000461303, 000461855 and 000464163.	Disclosed in part	10
A-2012-01642	AER for the product Aleve. Report number: 000448469.	Disclosed in part	1
A-2012-01643	AER for the product Maxidol. Report number: 000454918.	Disclosed in part	1
A-2012-01644	Documents relating to the Marihuana Medical Access Program for the personal use of designated person production licences in effect on December 31, 2012. And documents indicating how many people were charged by police in 2012 for having more marijuana plants or more stored marijuana than their licence allowed.	All disclosed	2
A-2012-01652	Copies of the Annual Statistical Report of Regulatory Advertising Activities prepared for/by Marketed Health Products Directorate's Regulatory Advertising Section. (Jan 1, 2006 to Mar 1, 2013).	All disclosed	9
A-2012-01672	AERs for the product Xarelto. Report numbers: 000464147 and 000467144.	Disclosed in part	3
A-2012-01673	AER for the product Yasmin. Report number: 000462322.	Disclosed in part	1
A-2012-01693	All audits and evaluations of Mental Health Service Providers under the Non-Insured Health Benefits Program. (Jan 1, 2011 to Mar 7, 2013).	No records exist	0
A-2012-01694	All documents for expenses paid by Department of Justice (Edmonton Office) to Health Canada concerning Employee Assistance Program (EAP) services. (Apr 01, 2009 to Jun 01, 2009).	No records exist	0
A-2012-01695	All documents regarding the effectiveness and/or results of the Non-Insured Health Benefits Prescription Monitoring Program. (Jan 1, 2007 to Mar 7, 2013).	Disclosed in part	31
A-2012-01697	All funding agreements between Health Canada and CANADIAN PARTNERSHIP AGAINST CANCER. (Jan 1, 2010 to Mar 3, 2013).	All disclosed	1
A-2012-01707	The total number of amalgam fillings and the associated expenditures for composite fillings billed to the Non-Insured Health Benefits program by dentists in Nunavut. (Jan 1, 1999 to Mar 12, 2013).	All disclosed	1
A-2012-01711	The overall number of Licenses to Produce Cannabis (marihuana) that have been issued by Health Canada under the Marihuana Medical Access Program to recipients within the District of Mission, British Columbia.	Disclosed in part	17